来自Polygonatum sibiricum的原料和葡萄酒加工多糖的低血糖效应和机制的比较研究
Hui Yang1, Shuhua Zhao2, Zhuoke Li1
1Shaanxi Academy of Traditional Chinese Medicine (Shaanxi Hospital of Traditional Chinese Medicine) Xi'an People's Republic of China.
Food science & nutrition
|December 10, 2025
概括
包括原油 (PSPC) 和葡萄酒加工 (PSPW) 在内的Polygonatum sibiricum多糖 (PSP) 显示出低血糖效应. 这两种形式都降低了氧化应激,并改善了胰岛素信号通路,PSPW在T2DM模型中展示了优越的好处.
科学领域:
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
- 传统中国医药 传统中国医药
背景情况:
- 众所周知,Polygonatum sibiricum多糖体 (PSP) 的低血糖性质是众所周知的.
- 葡萄酒加工PSP (PSPW) 在临床上普遍存在,但与原始PSP (PSPC) 相比,其机制研究不足.
- 了解PSPW的低血糖通路对于其治疗应用至关重要.
研究的目的:
- 评估PSPC和PSPW的低血糖效应和潜在机制.
- 为了比较PSPC和PSPW在2型糖尿病 (T2DM) 的细胞和动物模型中的疗效.
主要方法:
- 使用了HepG2细胞氧化应激模型和链毒素 (STZ) 诱导的T2DM大鼠模型.
- 评估的葡萄糖氧化酶 (GOD) 活性,活性氧物种 (ROS) 水平,肝/功能,血糖,脂质资料和胰岛素水平.
- 分析了关键胰岛素信号通路组件 (PI3K,AKT,INSR,GLUT-2) 的mRNA和蛋白质表达.
主要成果:
- 无论是PSPC还是PSPW,都降低了HepG2细胞中的GOD活性和ROS.
- 在T2DM大鼠中,PSPC和PSPW改善了肝/损伤,改善了禁食血糖 (FBG),并抵消了体重减轻.
- 在脂质谱,胰岛素水平和胰岛素信号通路激活 (PI3K/AKT/GLUT-2) 方面,PSPW表现出比PSPC更显著的改善.
结论:
- 通过减轻氧化应激和调节胰岛素信号通路,PSPC和PSPW具有低血糖作用.
- 与PSPC相比,PSPW在T2DM管理方面显示出增强的治疗潜力.
- 这些发现支持PSPW作为功能性食品成分和潜在的治疗剂的使用.
更多相关视频
相关概念视频
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
505
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
505
01:15Hypoglycemia and Glucagon
772
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
772
01:23Dipeptidyl Peptidase 4 Inhibitors
557
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
557
01:06Oral Hypoglycemic Agents: Glinides
565
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
565
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
562
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
562